The quest for new therapies in patients with cirrhosis and sepsis. Time to move from the lab to the bedside.
Quioc
Jean-Jacques
JJ
INSERM, U 773, Centre de Recherche Biomédicale Bichat-Beaujon CRB 3, Hôpital Beaujon, Clichy. quiocjj@yahoo.fr
Tazi
Khalid A
KA
Lebrec
Didier
D
Moreau
Richard
R
D000818:Animals; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D000925:Anticoagulants / Q000627:therapeutic use; D001424:Bacterial Infections / Q000150:complications / Q000188:drug therapy* / Q000276:immunology / Q000401:mortality / Q000503:physiopathology; D006801:Humans; D008103:Liver Cirrhosis / Q000150:complications* / Q000188:drug therapy* / Q000276:immunology / Q000401:mortality / Q000503:physiopathology; D008236:Lypressin / Q000031:analogs & derivatives / Q000627:therapeutic use; D010431:Pentoxifylline / Q000627:therapeutic use; D011486:Protein C / Q000627:therapeutic use; D016032:Randomized Controlled Trials as Topic; D051381:Rats; D018805:Sepsis / Q000150:complications / Q000188:drug therapy* / Q000276:immunology / Q000401:mortality / Q000503:physiopathology; D000077585:Terlipressin; D014662:Vasoconstrictor Agents / Q000627:therapeutic use
D000893:Anti-Inflammatory Agents; D000925:Anticoagulants; D011486:Protein C; D014662:Vasoconstrictor Agents; D008236:Lypressin; D000077585:Terlipressin; D010431:Pentoxifylline